Form 4: De Rosch Mark reports acquisition/exercise transactions in CRVO

Rhea-AI Filing Summary

De Rosch Mark reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Rosch Mark

(Last) (First) (Middle)

C/O CERVOMED INC.

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, RA and GA and PgM

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.8	02/11/2026		A		30,000		(1)	02/11/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CervoMed (CRVO) report for Mark De Rosch?

CervoMed reported that executive Mark De Rosch received a grant of 30,000 stock options on February 11, 2026. These options give him the right to buy CervoMed common stock, subject to a vesting schedule over 36 months beginning February 28, 2026.

How many CervoMed (CRVO) stock options were granted to Mark De Rosch?

Mark De Rosch was granted 30,000 CervoMed stock options. The options are reported as directly owned and will vest in 36 equal or near-equal monthly installments, starting on February 28, 2026 and continuing on the last calendar day of each month.

What is the exercise price and term of Mark De Rosch’s CervoMed (CRVO) stock options?

The granted stock options have an exercise price of $4.8 per share and expire on February 11, 2036. This gives a 10-year term from the grant date, assuming the options vest and remain outstanding under the specified vesting schedule.

How do the CervoMed (CRVO) options granted to Mark De Rosch vest over time?

The options vest in 36 equal, or as near equal as possible, monthly installments. Vesting occurs on the last calendar day of each month over a 36-month period, beginning on February 28, 2026, gradually increasing the number of exercisable shares.

What role does Mark De Rosch hold at CervoMed (CRVO) in this Form 4?

In the Form 4, Mark De Rosch is identified as an officer of CervoMed, serving as EVP, RA and GA and PgM. The reported transaction reflects a stock option award connected to his executive role, rather than an open-market purchase or sale.

Is the Mark De Rosch CervoMed (CRVO) Form 4 a purchase or a grant?

The Form 4 reflects a grant or award of stock options, coded as an acquisition (Code A), not an open-market share purchase. The options were granted at a $4.8 exercise price with no cash price reported for the derivative security at the time of grant.